Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,204 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,004 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04301778 | Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 |
| NCT02047474 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 46 | Yale UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04238715 | A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion | completed | Phase 2 | 63 | Eisai Co., Ltd.INDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT04526106 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 490 | Elevar TherapeuticsINDUSTRY | 13 | Feb 27, 2026 | clinicaltrials |
| NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | completed | Phase 1 / Phase 2 | 51 | Lokon Pharma ABINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04233567 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | completed | Phase 2 | 17 | Sameek RoychowdhuryOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04469556 | Pancreatic Adenocarcinoma Signature Stratification for Treatment(PASS-01) | completed | Phase 2 | 150 | University Health Network, TorontoOTHER | 2 | Feb 20, 2026 | clinicaltrials |
| NCT03983057 | Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer | completed | Phase 2 | 392 | Zhejiang UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03693807 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03092895 | A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | completed | Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03264404 | Azacitidine and Pembrolizumab in Pancreatic Cancer | completed | Phase 2 | 36 | Susan E. BatesOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04524702 | Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer | completed | Phase 2 | 10 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05641896 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers(18F-FAPI-74 GI) | completed | Phase 2 | 109 | SOFIEINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04550624 | Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma | completed | Phase 2 | 27 | Shanghai Jiahui International HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05348811 | HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | completed | Phase 2 | 25 | Zhongda HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03443492 | SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer(Pancreas) | completed | Phase 2 | 130 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07304388 | HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC | completed | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03745794 | Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery | completed | Phase 2 | 136 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05024513 | Biliary Drainage Plus HAIC in Locally Advanced pCCA | completed | Phase 2 | 127 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03910387 | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | completed | Phase 2 | 23 | Emory UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03193190 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | completed | Phase 1 / Phase 2 | 341 | Hoffmann-La RocheINDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT04054362 | Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma(PINBALL) | completed | Phase 2 | 27 | Barts & The London NHS TrustOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05052723 | Cabozantinib and Pembrolizumab in Metastatic Pancreas | completed | Phase 2 | 21 | Joseph KimOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT01489865 | ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 64 | Georgetown UniversityOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03192462 | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer(TACTOPS) | completed | Phase 1 / Phase 2 | 37 | Baylor College of MedicineOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05328167 | Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment | completed | Phase 2 | 16 | Thomas Jefferson UniversityOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT03404960 | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy(Parpvax) | completed | Phase 1 / Phase 2 | 104 | University of PennsylvaniaOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT03184870 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 332 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 9, 2025 | clinicaltrials |
| NCT03044587 | Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer(NIFE) | completed | Phase 2 | 93 | AIO-Studien-gGmbHOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT04257448 | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer(SEPION) | completed | Phase 1 / Phase 2 | 75 | GWT-TUD GmbHOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04264260 | Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment | completed | Phase 2 | 42 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT00964171 | Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer(PANTER) | completed | Phase 2 | 19 | Institut BergoniéOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04191421 | Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 35 | Emory UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT03579771 | Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer | completed | Phase 2 | 30 | Emory UniversityOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT04409002 | Niraparib + Dostarlimab + RT in Pancreatic Cancer | completed | Phase 2 | 18 | Massachusetts General HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | completed | Phase 2 | 147 | Incyte CorporationINDUSTRY | 12 | Aug 14, 2025 | clinicaltrials |
| NCT03697564 | Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer | completed | Phase 2 | 2 | Hitendra PatelOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03033225 | Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03377179 | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma | completed | Phase 2 | 65 | RedHill Biopharma LimitedINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT01781728 | Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma | completed | Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT01342354 | Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04923529 | TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma | completed | Phase 2 | 28 | The University of Hong KongOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 13, 2026source: clinicaltrials